128 related articles for article (PubMed ID: 32078355)
1. Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017-2018.
Weinstein LC; Iqbal Q; Cunningham A; Debates R; Landistratis G; Doggett P; Silverio A
Am J Public Health; 2020 Apr; 110(4):580-586. PubMed ID: 32078355
[No Abstract] [Full Text] [Related]
2. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.
Bachhuber MA; Thompson C; Prybylowski A; Benitez J; Mazzella S; Barclay D
Subst Abus; 2018; 39(2):167-172. PubMed ID: 29474119
[TBL] [Abstract][Full Text] [Related]
3. Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center.
Haddad M; Coman E; Bifulco L
Drug Alcohol Depend; 2024 Apr; 257():111252. PubMed ID: 38484404
[TBL] [Abstract][Full Text] [Related]
4. "It's a place that gives me hope": A qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center.
Lai S; Li E; Silverio A; DeBates R; Kelly EL; Weinstein LC
Subst Abus; 2021; 42(4):858-864. PubMed ID: 33492204
[No Abstract] [Full Text] [Related]
5. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.
Carter J; Li Z; Chen H; Greiner M; Bush C; Bhattacharya D; Poley S; Sachdeva N; Crowder JC; Feigal J
Addict Sci Clin Pract; 2022 Nov; 17(1):60. PubMed ID: 36335381
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
[TBL] [Abstract][Full Text] [Related]
7. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
[TBL] [Abstract][Full Text] [Related]
8. The role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study.
Giraldo A; Shah P; Zerbo E; Nyaku AN
Ann Med; 2024 Dec; 56(1):2355566. PubMed ID: 38823420
[TBL] [Abstract][Full Text] [Related]
9. Long-term retention in Office Based Opioid Treatment with buprenorphine.
Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
[TBL] [Abstract][Full Text] [Related]
10. Integration of Buprenorphine Treatment with Primary Care: Comparative Effectiveness on Retention, Utilization, and Cost.
Hsu YJ; Marsteller JA; Kachur SG; Fingerhood MI
Popul Health Manag; 2019 Aug; 22(4):292-299. PubMed ID: 30543495
[TBL] [Abstract][Full Text] [Related]
11. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
Campbell MD; Kolodner G; Spencer RA; DuPont RL
J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
Cunningham CO; Giovanniello A; Kunins HV; Roose RJ; Fox AD; Sohler NL
Am J Addict; 2013; 22(4):352-7. PubMed ID: 23795874
[TBL] [Abstract][Full Text] [Related]
13. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
Wakeman SE; McGovern S; Kehoe L; Kane MT; Powell EA; Casey SK; Yacorps GM; Irvin JR; Rodriguez W; Regan S
J Subst Abuse Treat; 2022 Oct; 141():108848. PubMed ID: 35926256
[TBL] [Abstract][Full Text] [Related]
14. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.
Riggins DP; Cunningham CO; Ning Y; Fox AD
Subst Abus; 2017; 38(3):297-302. PubMed ID: 27715904
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder.
Lopian KM; Chebolu E; Kulak JA; Kahn LS; Blondell RD
J Subst Abuse Treat; 2019 Feb; 97():1-6. PubMed ID: 30577894
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
17. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
[TBL] [Abstract][Full Text] [Related]
18. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
19. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
[TBL] [Abstract][Full Text] [Related]
20. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder.
Andraka-Christou B
Health Aff (Millwood); 2021 Jun; 40(6):920-927. PubMed ID: 34097509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
